Calcium Channel Blockers for Atrial Fibrillation: Verapamil & Diltiazem Dosing, Interactions, and Special Populations

Non-dihydropyridine calcium channel blockers (NDHP-CCBs)—verapamil and diltiazem—are first-line rate-control agents for atrial fibrillation (AFib). Dihydropyridines (amlodipine, nifedipine) are NOT used for rate control.

Mechanism in AFib

  • Block L-type calcium channels in SA/AV nodes → ↓ automaticity, ↑ refractory period, ↓ conduction velocity.
  • Effectively slow ventricular response at rest and during exercise.
  • No direct effect on atrial fibrillation maintenance (unlike antiarrhythmics).

Drug Selection

DrugFormulationsDosing (Rate Control)Key Features
VerapamilIR, SR, IVPO: 80–120 mg TID (IR) or 120–480 mg daily (SR); IV: 2.5–5 mg bolusMore negative inotropy; constipation common; CYP3A4 substrate
DiltiazemIR, ER, IVPO: 60–120 mg TID (IR) or 120–540 mg daily (ER); IV: 0.25 mg/kg bolus + infusionLess negative inotropy; preferred in mild HF; CYP3A4 substrate

Contraindications and Cautions

  • Absolute: Sick sinus syndrome (without pacemaker), 2nd/3rd degree AV block (without pacemaker), severe hypotension (SBP <90), cardiogenic shock.
  • Relative: HFrEF (verapamil contraindicated; diltiazem cautious), severe hepatic impairment, concurrent strong CYP3A4 inhibitors (clarithromycin, azoles, HIV protease inhibitors) or inducers (rifampin, carbamazepine).

Key Drug Interactions

  • Digoxin: Verapamil/diltiazem ↑ digoxin levels 50–75% → monitor levels.
  • Beta-blockers: Additive AV node suppression → bradycardia, heart block. Use cautiously; monitor HR.
  • Anticoagulants: Verapamil ↑ dabigatran (P-gp); diltiazem ↑ apixaban/rivaroxaban (CYP3A4/P-gp). Dose adjust per labeling.
  • Statins: ↑ simvastatin/lovastatin/atorvastatin levels → myopathy risk. Prefer pravastatin/rosuvastatin.
  • Grapefruit juice: Inhibits CYP3A4 → ↑ CCB levels.

Side Effects

  • Constipation (verapamil > diltiazem), peripheral edema, headache, dizziness, flushing, gingival hyperplasia (verapamil), bradycardia, AV block.
  • IV: Hypotension, asystole risk if bolus too fast.

Special Populations

  • Pregnancy: Category C. Diltiazem preferred if needed (more data). Avoid 1st trimester if possible.
  • Breastfeeding: Low milk transfer; generally compatible.
  • Elderly: Start low; monitor for hypotension, bradycardia, constipation.
  • HFrEF: Avoid verapamil; diltiazem may be used cautiously if rate control needed and beta-blocker maximized.

Monitoring

  • Heart rate (target resting <110 bpm; individualized), blood pressure, ECG (PR interval), electrolytes, renal/hepatic function.
  • Assess symptom control (palpitations, exercise tolerance).

CCBs are effective, well-tolerated rate-control options. Individualize choice based on comorbidities, interactions, and patient factors.

Ear Candling - Related Articles